In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Pinanong Na-PhatthalungDivision of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0002-8162-4645 Gabrielle van CaloenDivision of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0001-6827-7215 Marina PlanouteneDivision of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Emily TaiDivision of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Anisa GumerovaCenter of Translational Medicine and Pharmacology, Icahn School of Medicine at Mount Sinai, New York, NY.
Georgii PevnevCenter of Translational Medicine and Pharmacology, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0003-2015-9310 Jay CaoGrand Forks Human Nutrition Research Center, US Department of Agriculture, Grand Forks, ND.
Ronit WitztumDivision of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0009-0004-8987-1458 Eva IngberDivision of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Leon KautzIRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France.ORCID 0000-0002-2320-0457 Farhath SultanaCenter of Translational Medicine and Pharmacology, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0003-4186-3390 Funda KorkmazCenter of Translational Medicine and Pharmacology, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0002-9174-8369 Maayan LevyDivision of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0009-0001-0388-2649 Tony YuenCenter of Translational Medicine and Pharmacology, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0009-0001-6000-8827 Mone ZaidiCenter of Translational Medicine and Pharmacology, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0001-5911-9522 Yelena Z GinzburgDivision of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0002-3496-3783 Funding
Targeting FSH for the Therapy of Osteoporosis, Obesity and NeurodegenerationU19AG060917 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CLIFFORD JAMES ROSEN, Mone Zaidi · 2019 to 2026
$29.0MA Humanized Monoclonal FSH Blocking Antibody for Alzheimer's DiseaseU01AG073148 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Tony Yuen, Mone Zaidi · 2021 to 2026
$10.6MElevated FSH - A Driver for Sex Differences in Alzheimer's DiseaseR01AG074092 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HAROUTUNIAN, VAHRAM, YUEN, TONY · 2021 to 2025
$6.3MRegulatory Role of Transferrin in Erythropoiesis and Iron MetabolismR01DK095112 · NIDDK · SAINT LOUIS UNIVERSITY · PI Robert E Fleming, Yelena Ginzburg · 2012 to 2026
$5.4MThe Role of Erythroferrone in Regulating Bone Metabolism in Beta-ThalassemiaR01DK107670 · NIDDK · NEW YORK BLOOD CENTER · PI GINZBURG, YELENA, YUEN, TONY · 2015 to 2025
$4.5MProof-of-Concept and Mechanistic Studies to Repurpose Erectile Dysfunction Drugs for Elderly FemalesR01AG071870 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KIM, SE-MIN, YUEN, TONY · 2021 to 2025
$3.9MThyrotropin Receptor, Thyrotropin and Mechanisms of Bone LossR01DK113627 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI DAVIES, TERRY FRANCIS, IQBAL, JAMEEL Z · 2017 to 2020
$2.8MAAV-mediated Interrogation of the Brain FSH ReceptorR61AG094602 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GOOSENS, KI ANN, RYU, VITALY ANATOLIEVICH · 2025 to 2025
$2.1MNIA NIH HHS R01 AG071870NIA NIH HHS R01 AG074092NIA NIH HHS R61 AG094602NIA NIH HHS U01 AG073148NIA NIH HHS U19 AG060917NIDDK NIH HHS R01 DK095112NIDDK NIH HHS R01 DK107670NIDDK NIH HHS R01 DK113627
6 · The paper itselfAbstract
Erythroferrone (ERFE) secretion inhibits hepcidin expression by sequestering several bone morphogenetic protein (BMP) family members to increase iron availability for erythropoiesis. Recent evidence demonstrates that ERFE is also expressed in osteoblasts and osteoclasts and
Indexed as
bone formationerythroferroneosteoblastsosteoclaststransgenic mice
Identifiers
PMID42146409
PMCPMC13174593
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390